October is Breast Cancer Awareness Month, and this Saturday, WABC-TV will air a special feature, “Breast Cancer: Second Chances & New Advances” at 7:30PM. Hosted by Eyewitness News Anchor, Diana Williams, the breast cancer special highlights new advances that are helping those who are newly diagnosed or dealing with a recurrence.
While scientists work on the search for a cure, exciting progress has been made for those dealing with the worst form of breast cancer, triple negative breast cancer (TNBC). Dr. Linda Vahdat from the Weill Cornell Breast Center and NewYork-Presbyterian Hospital talks about the effects of copper depletion in the body. In addition to hearing about promising clinical trial results, hear from participating survivors who are living proof of the progress being made in the fight against TNBC, with hopes of FDA approval in the near future.
Additionally, doctors and researchers from other area medical centers share the latest on breast conservation for patients who have had a recurrence and new advances in immunotherapy offering targeted treatments for survivors.
This annual special is part of WABC-TV’s commitment to the American Cancer Society’s Making Strides Against Breast Cancer campaign. Learn more.
Earlier this week the U.S. News and World Report released their annual survey of “Best Hospitals”. NewYork Presbyterian one of the country’s largest and most comprehensive hospitals was ranked New York’s No. 1 hospital for the 16th year in a row, and No. 6 ranked hospital in all of the United States. Dr. Augustine M.K. Choi, interim dean of Weill Cornell Medicine commented,
“Our esteemed physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medicine always put patients first, providing them with the finest, most comprehensive care so that they can live their healthiest lives. Together we create one of the top academic medical centers in the United States, motivated by a shared commitment: to drive excellence in healthcare and truly make a difference in New York and beyond.”
This commitment is shared by the physicians, researchers, and staff in the Weill Cornell Breast Program.
Dr. Linda Vahdat is seeking women 18 years of age or older, diagnosed with metastatic triple negative breast cancer for a research study.
This clinical trial is for women with metastatic triple negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.
To learn more about the study and to see if you are eligible [go]
Dr. Linda Vahdat is seeking volunteers for a new research study in triple negative breast cancer.
This clinical trial is for women with metastatic triple-negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.
The purpose of this study is to evaluate the effectiveness and safety of eribulin mesylate (“eribulin”) in combination with pembrolizumab in metastatic (spread of cancer from one part of body to another) triple-negative breast cancer.
For more information visit our website
You can also find us on Twitter and Facebook